- Home
- SNPX vs BPTH Comparison
SNPX vs BPTH Comparison
Compare SNPX & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- BPTH
- Stock Information
- Founded
- SNPX 2012
- BPTH 2007
- Country
- SNPX United States
- BPTH United States
- Employees
- SNPX N/A
- BPTH N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- SNPX Health Care
- BPTH Health Care
- Exchange
- SNPX Nasdaq
- BPTH Nasdaq
- Market Cap
- SNPX 4.1M
- BPTH 4.0M
- IPO Year
- SNPX N/A
- BPTH N/A
- Fundamental
- Price
- SNPX $2.40
- BPTH $0.81
- Analyst Decision
- SNPX Strong Buy
- BPTH Strong Buy
- Analyst Count
- SNPX 1
- BPTH 2
- Target Price
- SNPX $14.00
- BPTH $30.00
- AVG Volume (30 Days)
- SNPX 18.6K
- BPTH 136.4K
- Earning Date
- SNPX 11-12-2024
- BPTH 11-15-2024
- Dividend Yield
- SNPX N/A
- BPTH N/A
- EPS Growth
- SNPX N/A
- BPTH N/A
- EPS
- SNPX N/A
- BPTH N/A
- Revenue
- SNPX N/A
- BPTH N/A
- Revenue This Year
- SNPX N/A
- BPTH N/A
- Revenue Next Year
- SNPX N/A
- BPTH N/A
- P/E Ratio
- SNPX N/A
- BPTH N/A
- Revenue Growth
- SNPX N/A
- BPTH N/A
- 52 Week Low
- SNPX $2.32
- BPTH $0.80
- 52 Week High
- SNPX $8.78
- BPTH $12.40
- Technical
- Relative Strength Index (RSI)
- SNPX 33.10
- BPTH 35.39
- Support Level
- SNPX $2.88
- BPTH $0.85
- Resistance Level
- SNPX $3.20
- BPTH $1.13
- Average True Range (ATR)
- SNPX 0.19
- BPTH 0.09
- MACD
- SNPX -0.06
- BPTH -0.01
- Stochastic Oscillator
- SNPX 8.88
- BPTH 3.91
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.